CTIS.eu › Cities › Spain › Madrid
Madrid
Spain
3,550 total trials
1,393 recruiting
Filter these 3,550 trials by phase, condition, sponsor and more.
Open in Search →
2024-515984-68-00
4
2025-05-20
Non-small cell lung cancer (NSCLC)
2024-513375-40-00
4
2025-05-16
Melanoma
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
2024-516615-25-00
1
2025-05-14
hepatocellular carcinoma (HCC)
2024-519822-18-00
10
2025-05-14
Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia
2023-506260-14-00
4
2025-05-13
multiple myeloma
2024-511102-22-00
4
2025-05-13
chronic myelomonocytic Leukemia
2024-513959-33-00
4
2025-05-13
Asthma
2024-517706-29-00
5
2025-05-13
Ataxia Telangiectasia
2024-519498-20-00
9
2025-05-13
Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplastic Syndrome (MD
2024-516605-23-00
5
2025-05-12
relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
2023-510155-37-00
5
2025-05-08
Hypomethylating agent (HMA) naive myelodysplastic syndromes
Myelodyspl
2024-515593-27-00
5
2025-05-08
relapsed or refractory mantle cell lymphoma (R/R MCL)
2024-517921-14-00
9
2025-05-07
Neuroendocrine tumors of midgut origin
2024-511915-21-01
1
2025-05-05
advanced or metastasic triple-negative breast cancer
2023-507030-24-00
4
2025-04-30
Persistent Corneal Epithelial Defects
2024-511435-10-00
1
2025-04-30
Hepatocellular Carcinoma
2024-515053-21-00
4
2025-04-30
Plasma cell leukaemia
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
2024-516030-35-00
5
2025-04-30
Multiple myeloma
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
Showing 1,081–1,104 of 3,550 trials